Related Experiment Video
Updated: Jul 25, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Clinical and genetic characteristics of PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome
Dan Zhang1, Gaixiu Su2, Yan Liu3
1Department of Rheumatology, Capital institute of pediatrics, 2 yabao road, chaoyang district, Beijing, China.
Insights
PAMI syndrome, a rare autoinflammatory condition, presents with myeloid-related proteinemia and can involve pyogenic arthritis and skin lesions. Genetic testing confirmed PSTPIP1 mutations in three pediatric patients, guiding treatment with immunosuppressants and biologics.
Area of Science:
- Genetics and immunology
- Pediatric rheumatology
- Rare autoinflammatory diseases
Background:
- PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome is a rare autoinflammatory disorder.
- Understanding its clinical and genetic spectrum is crucial for diagnosis and management.
Observation:
- Three pediatric patients with PAMI syndrome presented with recurrent trilineage hypoplasia, splenomegaly, and various inflammatory manifestations including pyoderma gangrenosum, Ludwig's angina, pyogenic arthritis, hepatomegaly, and pulmonary hypertension.
- Laboratory findings included elevated inflammatory markers (CRP, ESR) and specific autoantibodies or deficiencies in some patients.
- Genetic analysis revealed a consistent PSTPIP1 c.748G>A (p.E250K) heterozygous mutation in all three cases.
Findings:
- Treatment with glucocorticoids, immunosuppressants (cyclosporine, methotrexate), and cytokine antagonists (etanercept, infliximab) showed partial to significant improvement in clinical symptoms, inflammatory markers, and organomegaly.
- The PSTPIP1 mutation serves as a key diagnostic marker for PAMI syndrome.
Implications:
- PAMI syndrome requires a multidisciplinary approach involving geneticists, rheumatologists, and hematologists.
- Early diagnosis through genetic testing and prompt initiation of targeted therapies can improve patient outcomes.
- Further research into the pathogenesis and long-term management of PAMI syndrome is warranted.
Objective:
To summarise the clinical and genetic characteristics of three children with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome.
Methods:
This study retrospectively analysed the clinical and genetic data of three children with PAMI syndrome in our hospital between April 2018 and January 2020.
Results:
One male and two female children were 6 years and 5 months, 8 years and 7 months, and 13 years and 3 months of age. All three patients had a recurrent blood trilineage hypoplasia and splenomegaly. Patient 1 had pyoderma gangrenosum, and Ludwig's angina. Patient 2 had pyogenic arthritis, and pyoderma gangrenosum. Patient 3 had hepatomegaly, pyogenic arthritis, and pulmonary hypertension. Laboratory tests revealed that all three children had elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Patient 1: C-antineutrophilic cytoplasmic antibodies(c-ANCA), positive; antiglobulin test (Coombs), positive. Patient 2: blood zinc, 4.38 mg/L (elevated). Patient 3: Antinuclear antibodies (ANA), 1:100, β2 glycoprotein I, positive; Coombs test, positive; RF, 28.3 U/ml (elevated); C3, 0.77 g/L (decreased). Genetic testing showed that all 3 patients had PSTPIP1 c.748G > A (p.E250K) spontaneous heterozygous mutations, suggesting the diagnosis of PAMI syndrome. Patient 1 was treated with a combination of methylprednisolone and cyclosporine for 8 months. The patient did not develop new skin lesions. The blood count showed mild neutropenia. The spleen was considerably retracted and the CRP became normal. Patient 2 was treated with etanercept and methylprednisolone. The patient had no further arthralgias and pyoderma gangrenosum showed improvement. The spleen was smaller than before. White blood cells were shown to be approximately 2-3 × 109/L. The haematocrit, platelets, CRP, and AESR were normal. Patient 3 was treated with methylprednisolone, methotrexate, and infliximab 4 times. The patient's joint symptoms disappeared gradually and the liver retracted markedly. The pulmonary artery pressure returned to normal. Moreover, Coombs test result was negative. CRP and AESR were lower than before.
Conclusion:
PAMI syndrome can manifest as pyogenic arthritis, pyoderma gangrenosum, acne, and trilineage hypoplasia, as well as autoimmune diseases. Glucocorticoid and immunosuppressive therapy are partially effective and cytokine antagonists can be used in refractory cases. Whole-exome genetic testing is helpful to confirm diagnosis.
More Related Videos
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024